118 related articles for article (PubMed ID: 33456985)
1. Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
He W; Leng X; Wang K; Mao T; Peng L; Fang Q; Xiao W; Han Y
J Gastrointest Oncol; 2020 Dec; 11(6):1105-1112. PubMed ID: 33456985
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
4. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Liu G; Chen T; Zhang X; Hu B; Yu J
Cancer Med; 2024 Mar; 13(5):e7075. PubMed ID: 38477511
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
6. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
[TBL] [Abstract][Full Text] [Related]
7. Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy.
Yang Y; Zhang H; Liu Z; Ma N; Li C; Wang Y; Li Z
Ann Transl Med; 2023 Feb; 11(4):182. PubMed ID: 36923096
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
Zhao J; Hao S; Tian J; Li Y; Han D
J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
[TBL] [Abstract][Full Text] [Related]
9. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Yu YK; Meng FY; Wei XF; Chen XK; Li HM; Liu Q; Li CJ; Xie HN; Xu L; Zhang RX; Xing W; Li Y
J Thorac Cardiovasc Surg; 2024 Jan; ():. PubMed ID: 38246339
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial.
Wang YJ; Li KK; Xie XF; Bao T; Hao ZP; Long J; Wang S; Zhong ZY; Guo W
Front Oncol; 2022; 12():908841. PubMed ID: 35982957
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
13. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma.
Chen Y; Wu X; Hao D; Cheng X; Zhang L; Zhang Y; Ke S; Shi W; He C
Oncotarget; 2019 Jun; 10(40):4069-4078. PubMed ID: 31258850
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.
Tan Z; Yang H; Wen J; Luo K; Liu Q; Hu Y; Zhang L; Liu M; Yun J; Fu J
J Thorac Dis; 2018 Sep; 10(9):5254-5259. PubMed ID: 30416772
[TBL] [Abstract][Full Text] [Related]
16. Genomic and Transcriptomic Remodeling by Neoadjuvant Chemoradiotherapy (nCRT) and the Indicative Role of Acquired INDEL Percentage for nCRT Efficacy in Esophageal Squamous Cell Carcinoma.
Yang Y; Feng T; Fan X; Wang C; Jiang Y; Zhou X; Bao W; Zhang D; Wang S; Yu J; Tao Y; Song G; Bao H; Yan J; Wu X; Shao Y; Qiu G; Su D; Chen Q
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):979-993. PubMed ID: 37339686
[TBL] [Abstract][Full Text] [Related]
17. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
[TBL] [Abstract][Full Text] [Related]
18. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M
World J Surg; 2014 Aug; 38(8):2046-51. PubMed ID: 24615604
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
Zhan M; Zheng H; Yang Y; Xu T; Li Q
Radiother Oncol; 2019 Dec; 141():27-32. PubMed ID: 31431378
[TBL] [Abstract][Full Text] [Related]
20. Morphomic Factors Associated With Complete Response to Neoadjuvant Therapy in Esophageal Carcinoma.
Chiu CH; Zhang P; Chang AC; Derstine BA; Ross BE; Enchakalody B; Shah NV; Wang SC; Chao YK; Lin J
Ann Thorac Surg; 2020 Jan; 109(1):241-248. PubMed ID: 31550463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
